Paul Vilquin
Overview
Explore the profile of Paul Vilquin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
202
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vilquin P, Medard Y, Thomas F, Goldwirt L, Teixeira L, Mourah S, et al.
Cancer Chemother Pharmacol
. 2025 Jan;
95(1):16.
PMID: 39745516
The enzyme dihydropyrimidine dehydrogenase (DPD) is the primary catabolic pathway of fluoropyrimidines including 5 fluorouracil (5FU) and capecitabine. Cases of lethal toxicity have been reported in cancer patients with complete...
2.
Lebreton L, Boyer J, Lafay-Chebassier C, Hennart B, Baklouti S, Cunat S, et al.
Clin Pharmacol Ther
. 2024 Nov;
117(2):387-397.
PMID: 39584620
Mavacamten, the first drug in the class of β-cardiac myosin modulator, is used for the treatment of patients with hypertrophic cardiomyopathy. This orally administered drug demonstrates wide interpatient variability in...
3.
Reger De Moura C, Louveau B, Jouenne F, Vilquin P, Battistella M, Bellahsen-Harrar Y, et al.
Oncogene
. 2024 Apr;
43(21):1620-1630.
PMID: 38570692
The role of the focal adhesion protein kindlin-3 as a tumor suppressor and its interaction mechanisms with extracellular matrix constitute a major field of investigation to better decipher tumor progression....
4.
Maillard M, Louveau B, Vilquin P, Goldwirt L, Thomas F, Mourah S
Therapie
. 2021 Dec;
77(2):171-183.
PMID: 34922740
The discovery of molecular alterations involved in oncogenesis is evolving rapidly and has led to the development of new innovative targeted therapies in oncology. High-throughput sequencing techniques help to identify...
5.
Caputo S, Golmard L, Leone M, Damiola F, Guillaud-Bataille M, Revillion F, et al.
Am J Hum Genet
. 2021 Oct;
108(10):1907-1923.
PMID: 34597585
Up to 80% of BRCA1 and BRCA2 genetic variants remain of uncertain clinical significance (VUSs). Only variants classified as pathogenic or likely pathogenic can guide breast and ovarian cancer prevention...
6.
Lesueur F, Eon-Marchais S, Bonnet-Boissinot S, Beauvallet J, Dondon M, Golmard L, et al.
Cancers (Basel)
. 2021 Aug;
13(15).
PMID: 34359559
Assessment of age-dependent cancer risk for carriers of a predicted pathogenic variant (PPV) is often hampered by biases in data collection, with a frequent under-representation of cancer-free PPV carriers. TUMOSPEC...
7.
Louveau B, Resche-Rigon M, Lesimple T, Meda L, Pracht M, Baroudjian B, et al.
Clin Cancer Res
. 2021 May;
27(14):3876-3883.
PMID: 33947696
Purpose: In metastatic melanoma, cyclin D-CDK4/6-INK4-Rb pathway alterations are involved in resistance to MAPK inhibitors, suggesting a clinical benefit of cyclin-dependent kinase 4 (CDK4) inhibitors. In this phase I-II study,...
8.
Guissart C, Mouzat K, Kantar J, Louveau B, Vilquin P, Polge A, et al.
Sci Rep
. 2020 Nov;
10(1):20738.
PMID: 33244158
Amyotrophic lateral sclerosis (ALS) is the most common and severe adult-onset motoneuron disease and has currently no effective therapy. Approximately 20% of familial ALS cases are caused by dominantly-inherited mutations...
9.
Fabbro M, Colombo P, Leaha C, Rouanet P, Carrere S, Quenet F, et al.
Cancers (Basel)
. 2020 Aug;
12(8).
PMID: 32764409
High-grade serous ovarian cancers (HGSOC) are heterogeneous, often diagnosed at an advanced stage, and associated with poor overall survival (OS, 39% at five years). There are few data about the...
10.
Meulemans L, Mesman R, Caputo S, Krieger S, Guillaud-Bataille M, Caux-Moncoutier V, et al.
Cancer Res
. 2020 Feb;
80(7):1374-1386.
PMID: 32046981
Germline nonsense and canonical splice site variants identified in disease-causing genes are generally considered as loss-of-function (LoF) alleles and classified as pathogenic. However, a fraction of such variants could maintain...